Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy and safety of rapid intermittent correction and slow correction with an electrolyte-free solution in patients with severe hypernatremia (glucose-corrected serum sodium, ≥ 155 mmol/L).


Clinical Trial Description

Hypernatremia is defined as serum sodium (sNa) levels above 145 mmol/L and is caused by abnormalities in water balance, mainly in children, elderly, and critically ill patients. It occurs in 3% of hospitalized patients and in 9% of critically ill patients. Hypernatremia indicates hypertonic hyperosmolality and causes water outflow, resulting in cell dehydration. Most of the symptoms and signs of hypernatremia are due to brain abnormalities, which can progress to hyperventilation, muscle weakness, consciousness (lethargy), and coma. The short-term mortality rate of hypernatremia is 50%-60%. Decreased osmotic pressure in the extracellular fluid during correction of hyponatremia can cause cellular edema and permanent brain damage. The recommended sNa correction rate for acute hypernatremia is up to 1 mmol/L/h, whereas that for chronic hypernatremia is less than 0.5 mmol/L/h (approximately 10 mmol/L/day). However, these correction rates have only been studied and proven in pediatric patients. A recent study conducted on adults revealed that rapid correction (more than 0.5 mmol/L/h) was not associated with a higher risk for mortality, seizures, and alteration of consciousness. Several studies reported that excessively slow rates of sNa correction were associated with higher mortality, whereas rapid rates demonstrated lower mortality. There are no established guidelines for the Na correction rate for hypernatremia. The European and American guidelines recommend infusion of electrolyte-free water (10 mL/kg over 1 h or 3 mL/kg/h) for the management of overcorrection of hyponatremia. In the previously published SALSA I trial, 10 mL/kg over 1 h was applied as a method of re-lowering treatment in overly rapid correction of hyponatremia. However, this rapid intermittent bolus of electrolyte-free water has never been applied to treat hypernatremia. The aim of this prospective, randomized, open-labeled, multi-center, and investigator-initiated trial is to determine whether a rapid and intermittent bolus of electrolyte-free water in hypernatremia can increase the incidence of rapid decrease in sNa level and increase the survival time compared to the slow continuous administration method. A total of 166 patients with severe hypernatremia will be enrolled and randomly assigned to receive either intermittent bolus or slow continuous infusion of 5% dextrose water. The participants will be divided into three groups according to age and sex and will receive 5% dextrose water for 2 days at different correction rates. Serum sodium will be measured every 3 h from the beginning to 6 h, followed by every 6 h until 48 h. In addition, urine sodium and potassium levels will be measured at baseline and 24 h. The PP (Per Protocol) analysis will be applied to enrolled participants who is infused with 75-125% of total planned volume of 5% dextrose water. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04949139
Study type Interventional
Source Seoul National University Hospital
Contact Sejoong Kim, PhD
Phone +821094964899
Email sejoong2@gmail.com
Status Recruiting
Phase Phase 4
Start date May 1, 2021
Completion date May 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT02926989 - Intravenous Fluids in Hospitalised Children Phase 4
Not yet recruiting NCT05085223 - Prospective Analysis Into Development of Hypernatremia in Critically Ill Patients
Completed NCT01456533 - Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients N/A
Withdrawn NCT01326429 - Frequency and Origin of Dysnatremias in the Emergency Department N/A
Recruiting NCT03658850 - Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients Phase 2
Not yet recruiting NCT06061783 - Correction of Hypernatremia by Intravenous Hypotonic Solution Compared to Enteral Water N/A
Completed NCT02912299 - Investigation on Differences in Skin Sodium Content Between Normal Subjects and ICU-patients N/A
Completed NCT01219179 - Use of Sterile Water Feeds for Treatment of Hypernatremia in Extremely Low Birth Weight Infants N/A
Completed NCT03752450 - Prospective Data Analysis of the Development of Hypernatremia in Intensive Care Unit
Completed NCT00734214 - Hypotonic Versus Isotonic Parenteral (HIP) Fluid Trial Phase 3
Recruiting NCT02449382 - Continuous Venovenous Hemofiltration Versus Conventional Treatment for Acute Severe Hypernatremia N/A
Withdrawn NCT01617798 - Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis N/A
Recruiting NCT05818826 - Early Versus Conventional Cessation of Hydrocortisone in Septic Shock Phase 2
Recruiting NCT01299428 - Evaluation of the Cerebral Oxygenation With Near Infrared Spectrophotometry (NIRS) at the Hypernatremic Dehydration in Newborn N/A
Recruiting NCT04265976 - ED Hypernatremia. Prognostic Factors and Epidemiology.
Completed NCT03610074 - Relieve the Patient's Thirst, Refresh the Mouth First (ICU-MIC) N/A